ATP2B1

ATP2B1 rs17249754 — A Second Calcium Pump Variant Tuning Blood Pressure

Running just 80 kilobases downstream of the widely-studied rs2681472 variant at
the same gene, rs17249754 is an independent intronic variant in ATP2B1 | encodes
Plasma Membrane Ca²⁺-ATPase 1 (PMCA1), the primary pump ejecting calcium from
inside cells to the extracellular space — essential for maintaining low intracellular
calcium in vascular smooth muscle. Like its
neighboring variant, rs17249754 has reached genome-wide significance in multiple
large international consortia, but its risk story has an unusual twist: the common G
allele (~83% in Europeans, ~65% in East Asians) is the blood pressure-raising
allele, while the rarer A allele is protective. Most people carry at least one G allele
without knowing it.

The Mechanism

rs17249754 sits within an intron of ATP2B1 on chromosome 12q21.33, position
89,666,809 (GRCh38). The intronic
location means it does not alter the protein sequence of PMCA1 directly; instead,
it acts as a regulatory variant affecting gene expression levels in vascular tissue.
The G allele is associated with reduced ATP2B1 expression in arterial and aortic
endothelial cells — fewer functional PMCA1 pumps per cell.

PMCA1 is the dominant calcium extrusion mechanism in vascular smooth muscle cells.
When pump density falls, intracellular calcium rises, driving sustained smooth muscle
contraction and vasoconstriction. Separately, PMCA1 physically associates with
eNOS | endothelial nitric oxide synthase, which produces the vasodilator nitric
oxide: impaired PMCA1 activity reduces
eNOS output, removing a key vasodilatory signal. Both effects — higher calcium and
lower nitric oxide — converge on elevated vascular resistance and raised blood
pressure.

Mouse models directly validate this pathway: heterozygous PMCA1-null animals develop
elevated blood pressure, and vascular smooth muscle-specific knockout mice show
increased intracellular calcium with hypertension. Strikingly, aging heterozygous
PMCA1-null mice exhibit arterial wall thickening and lumen narrowing before blood
pressure rises, suggesting subclinical
vascular remodelling may precede measurable hypertension by years.

The Evidence

The ICBP consortium analysis | International Consortium for Blood Pressure
Genome-Wide Association Studies in
approximately 200,000 European-ancestry participants placed rs17249754 among 29
genome-wide significant blood pressure loci: each G allele raises systolic BP by
0.928 mmHg (p=1.8×10⁻¹⁸) and diastolic BP by 0.522 mmHg (p=1.2×10⁻¹⁴). These
effect sizes are per-allele, meaning GG homozygotes carry approximately 1.86 mmHg
higher systolic and 1.04 mmHg higher diastolic BP than the rare AA genotype.

The original Korean discovery in
16,703 Korean participants (KARE and Health2 cohorts) found rs17249754 was the
strongest ATP2B1 signal for hypertension (p=4.25×10⁻⁹) — stronger than the
neighboring rs2681472, which predominates in European analyses. A 2021 meta-analysis
of 65,362 individuals across 9 studies
confirmed the association globally: hypertension OR=1.19 (95%CI 1.10–1.28) per G
allele. Cross-ethnic replication in 55,383 East Asian participants (stage 1+2)
confirmed the locus for mean arterial pressure (p=7.5×10⁻¹⁵) and pulse pressure
(p=1.2×10⁻⁵). Replication extends to African (Burkina Faso), Chinese children,
and South Asian populations.

A critical dietary interaction has been documented. In a Korean cohort of 14,354
participants, G allele (major allele)
carriers showed substantially higher systolic BP risk when calcium intake was low
and the dietary sodium-to-potassium ratio was high. Conversely, A allele carriers
(the protective minority) gained the greatest benefit from high potassium intake and
a low sodium-to-potassium ratio. This gene-diet interaction is directly actionable:
PMCA1 insufficiency from the G allele is exacerbated when dietary calcium is
unavailable to compensate for impaired efflux.

Practical Actions

For GG carriers, three strategies target the underlying mechanism most directly.
Maintaining dietary calcium at 1,000–1,200 mg/day is the most genotype-specific
intervention: low calcium amplifies the blood pressure risk from reduced PMCA1
activity at a cellular level. Reducing the dietary sodium-to-potassium ratio —
through sodium reduction and potassium-rich foods — addresses the salt-sensitivity
component documented in this variant's cohort studies. Regular home blood pressure
monitoring enables early detection of the gradual pressure elevation this variant
drives. For AG heterozygotes, the same dietary targets apply with attenuated
urgency — the additive effect model means they carry approximately half the
genotype-attributable BP elevation.

Interactions

rs17249754 and rs2681472 are both intronic ATP2B1 variants in partial linkage
disequilibrium. rs2681472 is the stronger signal in European-ancestry GWAS;
rs17249754 is stronger in East Asian cohorts. Carriers of risk alleles at both
variants may have compounded calcium-mediated BP elevation, though formal compound
action studies documenting the interaction effect are not yet published.

Within the blood pressure regulatory network, ATP2B1 interacts functionally with
AGT (rs699, angiotensinogen M235T) and NOS3 (rs1799983, eNOS Glu298Asp).
Angiotensin II elevates intracellular calcium in vascular smooth muscle — a signal
that depends on PMCA1 for clearance. Reduced PMCA1 in G allele carriers means
angiotensin II-driven calcium signals persist longer. Similarly, impaired PMCA1
reduces the calcium/calmodulin signal available to activate eNOS, compounding
the effect of any eNOS Glu298Asp-associated nitric oxide deficit.